News | August 12, 2025
Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad
This strategic investment strengthens Cohance's integrated oligonucleotide platform
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
Site Enhances New Modality CRDMO Platform Capacity for Customers
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
The investment will increase SpeeDx internal capacity to scale up manufacturing
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Subscribe To Our Newsletter & Stay Updated
